Use of Dispersible Fixed-Dose Combinations in Chemotherapy of Drug Susceptible Tuberculosis: Results of the Observational Study
https://doi.org/10.58838/2075-1230-2024-102-4-56-62
Abstract
The objective: to assess effectiveness, safety and pharmacoeconomic feasibility of using a dispersible fixed-dose combination (isoniazid 150 mg, rifampicin 150 mg, pyrazinamide 375 mg) in patients with respiratory tuberculosis and preserved susceptibility of Mycobacterium tuberculosis (MTB) to anti-tuberculosis drugs.
Subjects and Methods. A post-registration observational study was conducted to assess treatment effectiveness of pulmonary tuberculosis in 60 adult patients with drug susceptible tuberculosis. In Main Group, patients received the fixed-dose combination (isoniazid 150 mg, rifampicin 150 mg, pyrazinamide 375 mg), while in Control Group, patients were treated with the regimen consisting of single anti-tuberculosis drugs.
Results. Sputum conversion rate made 76.7% by the end of the intensive phase (60 doses) when replacing isoniazid, rifampicin and pyrazinamide with the dispersible fixed-dose combination, while with the standard choice of drugs, it was 66.7%. The incidence of adverse reactions was 7-fold lower when using the investigational drug which contributed to a high level of adherence and high effectiveness of therapy. Pharmacoeconomic analysis convincingly demonstrated advantages and economic benefits of the dispersible fixed-dose combination (isoniazid 150 mg, rifampicin 150 mg, pyrazinamide 375 mg), which was more costly than the combination of single drugs.
About the Authors
E. S. Nikitina
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Ekaterina S. Nikitina, Deputy Head of Clinic no. 2
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
O. S. Ilyina
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Olga S. Ilyina, Head of Clinic no. 2
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
O. D. Baronova
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Olga D. Baronova, Doctor of Medical Sciences, Deputy Head Physician for Out-Patient Medical Care, Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
References
1. Kavtarashvili S.M., Kazakov A.V., Milyankova I.E., Madasova V.G. Adherence to tuberculosis treatment when using dispersible tablets in children and adolescents. Meditsinsky Alyans, 2015, no. 3, pp. 76-79. (In Russ.)
2. Kuzmina N.V., Nelidova N.V., Gerasimova N.V. Experience of using Ftizamax in treatment of tuberculosis patients. Fundamentalnyye i prikladnyye problemy zdorovyesberezheniya cheloveka na Severe: sbornik materialov III Vserossiyskoy nauchno-prakticheskoy konferentsii, Surgut, 20-21 oktyabrya 2018 goda. [Fundamental and Applied Problems of Human Health in the North: Abst. Book of the III All-Russian Scientific and Practical Conference, Surgut, October 20-21, 2018]. Surgut, Surgutskiy Gosudarstvennyy Universitet Publ., 2018, pp. 146-148. (In Russ.)
3. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2019 year. Gosudarstvenny doklad. [State report on the state on sanitary and epidemiological welfare of population in the Russian Federation in 2019]. Moscow, Federalnaya Sluzhba po Nadzoru v Sfere Zaschity Prav Potrebiteley i Blagopoluchiya Cheloveka Publ., 2020, 299 p.
4. Smirnov A.P., Mashkina E.A. Use of cost-effectiveness pharmacoeconomical analysis at the choice of one of alternative options of treatment in clinical practice International Research Journal, 2016, vol. 51, no. 9, pp. 85-86. (In Russ.)
5. Filippenko N.G., Povetkin S.V. Metodologiya kliniko-ekonomicheskogo issledovaniya (farmakoekonomicheskiy analiz v tablitsakh i skhemakh). [Methodology of clinical and economic research (pharmacoeconomic analysis in tables and diagrams)]. Kursk, KGMU Publ., 2005, 29 p.
6. Yagudina R.I., Kulikov A.Yu., Serpik V.G., Protsenko M.V., Goloenko N.G. Development of pharmacoeconomic analysis according to current requirements of the health care system of the Russian Federation. Scientific Centre for Expert Evaluation of Medicinal Products Bulletin, 2014, no. 3, pp. 56-61. (In Russ.)
7. Apis V., Landi M., Graham S.M. et al. Outcomes in children treated for tuberculosis with the new dispersible fixed-dose combinations in Port Moresby. Public Health Action, 2019, no. 9, suppl. 1, pp. S32-S37. https://doi.org/10.5588/pha.18.0062
8. Suárez-González J., Santoveña-Estévez A., Soriano M., Fariña J.B. Design and optimization of a child-friendly dispersible tablet containing isoniazid, pyrazinamide, and rifampicin for treating tuberculosis in pediatrics. Drug Dev. Ind. Pharm., 2020, vol. 46, no. 2, pp. 309-317.
Review
For citations:
Nikitina E.S., Ilyina O.S., Baronova O.D. Use of Dispersible Fixed-Dose Combinations in Chemotherapy of Drug Susceptible Tuberculosis: Results of the Observational Study. Tuberculosis and Lung Diseases. 2024;102(4):56-62. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-4-56-62
Views:
178
Email this article 